- Home
- AYRO vs ENSC Comparison
AYRO vs ENSC Comparison
Compare AYRO & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AYRO
- ENSC
- Stock Information
- Founded
- AYRO 2017
- ENSC 2003
- Country
- AYRO United States
- ENSC United States
- Employees
- AYRO N/A
- ENSC N/A
- Industry
- AYRO Telecommunications Equipment
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- AYRO Consumer Discretionary
- ENSC Health Care
- Exchange
- AYRO Nasdaq
- ENSC Nasdaq
- Market Cap
- AYRO 4.8M
- ENSC 5.5M
- IPO Year
- AYRO N/A
- ENSC N/A
- Fundamental
- Price
- AYRO $0.53
- ENSC $2.29
- Analyst Decision
- AYRO
- ENSC
- Analyst Count
- AYRO 0
- ENSC 0
- Target Price
- AYRO N/A
- ENSC N/A
- AVG Volume (30 Days)
- AYRO 90.4K
- ENSC 31.4K
- Earning Date
- AYRO 05-14-2025
- ENSC 05-12-2025
- Dividend Yield
- AYRO N/A
- ENSC N/A
- EPS Growth
- AYRO N/A
- ENSC N/A
- EPS
- AYRO N/A
- ENSC N/A
- Revenue
- AYRO $63,777.00
- ENSC $5,210,031.00
- Revenue This Year
- AYRO N/A
- ENSC N/A
- Revenue Next Year
- AYRO N/A
- ENSC N/A
- P/E Ratio
- AYRO N/A
- ENSC N/A
- Revenue Growth
- AYRO N/A
- ENSC 133.58
- 52 Week Low
- AYRO $0.49
- ENSC $2.12
- 52 Week High
- AYRO $1.66
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- AYRO 45.06
- ENSC 20.64
- Support Level
- AYRO $0.50
- ENSC $2.19
- Resistance Level
- AYRO $0.77
- ENSC $2.70
- Average True Range (ATR)
- AYRO 0.06
- ENSC 0.32
- MACD
- AYRO 0.00
- ENSC -0.06
- Stochastic Oscillator
- AYRO 9.67
- ENSC 5.69
About AYRO AYRO Inc.
AYRO Inc design and manufacture compact, sustainable electric vehicles for closed campus mobility, low-speed urban and community transport, local on-demand and last-mile delivery, and government use. It operates as one reportable segment, which is the design, development, manufacturing, and sales of electric vehicles, and operates in the United States.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.